This
is a tremendously exciting time as we deliver the benefits of Agency
transformation to enhance our vital role in the safeguarding of public health.
The Chair will play a
key role in driving forward the strategic direction of the Agency to maintain the
UK as a global centre of excellence in medical science, in the best interests
of patients and the public.
Dr June Raine DBE, CEO of MHRA
The Chair of the MHRA is accountable to the Secretary of State for Health and Social Care and will:
The Medicines and Healthcare products Regulatory Agency enhances and improves the health of millions of people every day through the effective regulation of medicines and medical devices, underpinned by science and research.
Recognised globally as an authority in its field, the agency plays a leading role in protecting and improving public health and supports innovation through scientific research and development.
The agency is made up of c.1300 staff working across two main centres, in Canary Wharf as part of the Government Hub, and in South Mimms near Potters Bar, where their laboratories are located. There are also staff who work peripatetically across the UK and abroad.
The agency consists of 6 Groups - Corporate, Enablement, Scientific Research & Innovation, Healthcare Quality & Access, Safety & Surveillance and Digital and Technology.
The agency is responsible for:
- ensuring that medicines, medical devices and blood components for transfusion meet applicable standards of safety, quality and efficacy
- ensuring that the supply chain for medicines, medical devices and blood components is safe and secure
- promoting international standardisation and harmonisation to assure the effectiveness and safety of biological medicines
- helping to educate the public and healthcare professionals about the risks and benefits of medicines, medical devices and blood components, leading to safer and more effective use
- supporting innovation and research and development that’s beneficial to public health
- influencing UK, EU and international regulatory frameworks so that they’re risk-proportionate and effective at protecting public health.
The Delivery Plan 2021-2023 ‘Putting patients first; A new era for our agency’, sets out the agency’s objectives and deliverables across six core themes:
- Collaborative partnerships
These are underpinned by the priority to develop and improve patient and public involvement. For more information see Our governance - Medicines and Healthcare products Regulatory Agency - GOV.UK (www.gov.uk)
The MHRA Board
The MHRA operates a unitary Board, the role of which is to provide strategic advice on the running of the Agency, ensuring that effective arrangements are in place to:
- Provide assurance and review the controls needed for effective risk management, governance and internal control.
- Demonstrate sound financial management and good value for money.
- Ensure that the Agency has the capability to deliver.
Specifically, the Board is collectively responsible for the following:
- Agreeing the strategic aims and objectives of the Agency, consistent with its overall strategic direction and within the policy and resources framework determined by the Secretary of State.
- Endorsing the Agency’s recommendations to Ministers on the Agency’s key financial and performance targets and the Agency’s annual business plan and five-year corporate plan.
- Agreeing the content of the Agency’s annual report to be proposed to Ministers.
- Advising on and monitoring: - The implementation of strategies to ensure that the regulatory systems for medicines and medical devices are effective and robust, given developments in science and technology, at a UK and international level;
- The implementation of strategies for increasing public knowledge and understanding about the safe use of medicines and medical devices
- The service provided to the manufacturers of medicines and medical devices, to health and social care professionals and to the general public
- The steps taken by the Agency to protect the interests of the public by ensuring that medicines meet appropriate standards of safety, quality and efficacy and that medical devices meet appropriate standards of safety, quality and performance; and
- The steps taken by the Agency to support innovation and growth and the impact these have had on public health.
- Board meetings dates are generally arranged
for the third Tuesday of every month.
The main office location is at 10 South Colonnade, Canary
Wharf, London, E14 4PU.
Our governance - Medicines and Healthcare products Regulatory Agency - GOV.UK (www.gov.uk)